Stock OXMDGG MEDIGENE NA
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News MEDIGENE NA Swiss Exchange

Equities

OXMDGG

DE0005020903

End-of-day quote Swiss Exchange
Other stock markets
- EUR - Intraday chart for MEDIGENE NA
05-21 Medigene, BioNTech Extend Cancer Immunotherapy Partnership MT
05-21 Medigene AG's Global Research & Collaboration Agreement with BioNTech SE to Extend Beyond Initial Announced Term CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent Office
GL
Medigene, BioNTech Extend Cancer Immunotherapy Partnership
MT
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term
GL
Medigene AG's Global Research & Collaboration Agreement with BioNTech SE to Extend Beyond Initial Announced Term
CI
Medigene : Description of the remuneration system for Supervisory Board members
PU
Medigene : Report of the Executive Board on agenda item 8
PU
Medigene : Report of the Executive Board on agenda item 9
PU
Medigene : Explanations of the rights of shareholders
PU
Medigene : Proxy to third person
PU
Medigene : Data protection information
PU
Medigene : CV Dr. Gerd Zettlmeissl
PU
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
GL
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
AQ
Medigene AG Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
CI
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
GL
Medigene Ag Maintains Earnings Guidance for 2024
CI
Medigene Boosts Share Capital Via Rights Offering, Private Placement
MT
Medigene to Present at Upcoming Conferences
GL
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 targeted T Cell Receptor
AQ
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MDG1 Stock
  4. OXMDGG Stock
  5. News MEDIGENE NA